Novel polymer-based super-absorbent dressing will be first of its kind in
US and Canada
PRINCETON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced the commercial launch of its newest product -- XTRASORB(TM) Super Absorbent Dressing. The novel dressing features a polymer-based core that could help change the way clinicians manage heavily exuding wounds, currently a significant issue in wound care. The dressing will be launched at next week's Clinical Symposium on Advances in Skin & Wound Care in Las Vegas.
Commenting on the launch, CEO Ed Quilty stated, "This is something we have been excited about for quite a while. Foam dressings, for highly exuding wounds, is the single largest category of moist wound dressings, with over $300 million in global sales. Still, even the best dressings in this category have limitations. Clinicians still want dressings to hold more fluid to reduce the number of time-consuming and costly dressing changes. Additionally, the fluid that a foam dressing does absorb is at a high risk of being pushed back onto the wound bed, potentially causing serious complications to the wound. For these reasons, our market research shows that clinicians will love the fact that XTRASORB can absorb roughly 50% more than even the most absorbent foam dressing, and that the polymer-based super-absorbent core forms a gel which locks all the wound fluid inside the dressing and away from the wound. This has multiple benefits, including reducing the risk of wound breakdown due to excessive moisture, as well as keeping harmful bacteria often found in wound fluid away from the wound."
Quilty continued, "Based on our research and feedback from customers, we are extremely confident that we will have another successful product launch. We launched MEDIHONEY(R) Dressings last year at the Clinical Symposium, and we have done very well with that product. Our expectations for XTRASORB are very high, and we look forward to it being a significant contributor to our overall growth moving forward. This is yet another step in the course we've charted out over the past several years -- using the cash flow from our $50+ million revenue baseline business to fund the development of novel higher margin advanced wound care products, and then to launch and support them with marketing and our growing sales organization. This is what is going to drive our topline growth and profitability."
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced
wound-care products. Its key product, MEDIHONEY, is sold throughout the
world by Derma Sciences and Comvita New Zealand -- the licensor of the
patented honey-based technology -- and is the leading brand of honey-based
dressings for the management of wounds and burns. The product has been
shown to be effective in a variety of wounds and burns, and was recently
the focus of a positive large-scale randomized controlled trial on leg
ulcers. Derma has two products in development: the BIOGUARD(TM) line of
barrier gauze dressings, and DSC127, the company's novel angiotensin analog
for accelerated wound healing and scar reduction. The barrier technology
was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA
marketing clearance. DSC127 was licensed from The University of Southern
California in Q4 of 2007 and is entering into a Phase II study, with
anticipated initial patient enrollment to begin in Q3 of 2008. For more
information about Derma Sciences, Inc., visit its home page on the Internet
Contact: Derma Sciences, Inc. Allen & Caron Inc
Edward J. Quilty Rudy Barrio (US Investors)
Chairman and CEO email@example.com
(609) 514-4744 Brian Kennedy (media)
|SOURCE Derma Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved